In a Brief Report titled "Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial," published in JAMA Cardiology ...

Secondary efficacy and pharmacodynamic endpoints were also met in the trial. Rivus is now preparing to discuss a Phase III ...

Novartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction (HFpEF) and isn’t letting a missed endpoint scupper the programme.

Drugmaker Rivus Pharmaceuticals had previously announced plans to proceed to a phase III trial for HU6 in obesity HFpEF next year. Meanwhile, a treatment specifically indicated for obesity-related ...

All in all, it is clear that semaglutide has the potential to be popular among HFpEF patients and clinicians alike, given the promising results from its SELECT trial. Thus, semaglutide is on a ...

The findings mirrored those of the similarly designed STEP-HFpEF trial in a population without type 2 diabetes. A pooled ...

11 The trial, initiated in 2018, enrolled 17,604 adults and was conducted in 41 countries at more than 800 investigator sites. 11 About the STEP-HFpEF trial (semaglutide 2.4 mg) STEP-HFpEF was a ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Its basic plan starts at $23 a month, billed annually, and it has a 15-day free trial. How do I know I can trust these reviews about The Neat Company? How do I know I can trust these reviews about ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window There may be a future for cardiac myosin inhibitors in ...